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Abstract: Fibroblast growth factors (FGF) are involved in a wide range of biological processes 
such as cell proliferation and differentiation. In living organisms, the binding of FGF to its 
receptors are mediated through electrostatic interactions between FGF and naturally occurring 
heparin. Despite its prevalent use in medicine, heparin carries notable limitations, namely; its 
extraction from natural sources (expensive, low yield and extensive purification), viral 
contamination, and batch-to-batch heterogeneity. In this work a range of synthetic homopolymers 
and copolymers of sodium 2-acrylamido-2-methylpropane sulfonate (AMPS®) were evaluated as 
potential FGF stabilisers. This was studied by measuring the proliferation of BaF3-FR1c cells, as 
a model assay, and the results will be compared with the natural stabilisation and activation of 
FGF by heparin. This study explores the structure-activity relationship of these polysulfonated 
polymers with a focus on the effect of molecular weight, co-monomer type, charge dispersion and 
polymer architecture on protein stabilisation. 
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Introduction 
The stabilisation of fibroblast growth factors (FGF) is a widely studied phenomenon which has 
implications in important cellular processes such as proliferation, differentiation and motility.1-5 
FGFs are typically activated through the dimerization of two FGF molecules via electrostatic 
interactions between the positively charged domains of fibroblast growth factors and the 
negatively charged polysaccharide, heparin. The binding of these dimers to cell surface fibroblast 
growth factor receptors then induces a variety of biochemical cascades, stimulating the above 
cellular processes.6-7,8 The stabilisation of FGFs is therefore vital for applications such as wound 
healing, due to its role in fibroblast proliferation. Heparin involvement in the proliferation process 
is manifold; as the sulfated glycosaminoglycan not only acts as a co-factor of FGF, it was also 
shown to activate FGFRs and promote the dimerisation of the receptors.2, 4, 9-14 Environmental 
stressors associated with storage and transport (e.g. thermal stressors) are known to lead to FGF 
degradation and inactivation, and heparin has been shown to protect and stabilise FGF during 
storage.5, 15 Heparin uses are however limited by high cost of extraction, potential adverse side 
effects and most importantly, batch-to-batch dependency.16-20 With this consideration, researchers 
have been extensively investigating replacing heparin with other synthetic (macro)-molecules.16, 
21 
 
The most popular approach to generating synthetic heparin mimics is through the full or partial 
sulfation of natural chitosan.22 While these natural polymers allow for control over molecular 
weight, they are prone to desulfation, and consequently a loss in biological activity. Modern 
polymerisation techniques introduce the possibility to incorporate functional groups that enhance 
the versatility of these potential FGF stabilisers without the above drawbacks.22-27 Maynard et al. 
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studied a range of synthetic sulfated polymers as heparin-mimicking polymers to stabilise FGF.28-
31 Overall, they found that PVS (poly(sodium vinyl sulfonate)) and PAHPS (poly(sodium 1-
allyloxy-2 hydroxypropyl sulfonate)) stimulate BaF3-FR1c cell proliferation in a comparable way 
to heparin, while PAMPS acted like an inhibitor (antiproliferative) to BaF3-FR1c cell proliferation 
at high concentrations (100 µg/mL) while showing little to no activity at lower concentrations.28 
Garcia-Fernandez et al. also demonstrated this antiproliferattive effect of PAMPS but towards 
Balb/c 3T3 fibroblast cells in the presence of FGF. They studied two copolymers, containing 2-
acrylamido-2-methylpropane sulfonate (AMPS®) and either a hydrophilic monomer (1-vinyl-2-
pyrrolidinone), or a hydrophobic monomer (butyl acrylate), prepared using free radical 
polymerisation, as heparin mimics. The antiproliferative activity was modulated by varying either 
the polymer concentrations in the cell media or by varying the copolymer composition.32-33 
 
Here, we report a systematic study on the effect of molecular weight, comonomer type and 
polymer architecture on FGF activation/stabilisation efficiency, using PAMPS homopolymers and 
copolymers prepared by aqueous RAFT polymerisation.34 The efficiency of FGF stabilisation by 
the synthetic polymers was evaluated in vitro by quantifying the proliferation of IL-3 dependant 
murine pro B cell line (BaF3-FR1c), which has been modified to express FGFR1c but lacks 
extracellular heparan sulfates.12 The thermal stabilisation of FGF by heparin-mimicking polymers 
was further evaluated by applying temperature stressors on FGF in the presence or absence of 
sulfonated polymers, and compared to heparin itself.  
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Scheme 1: Structures of the polymers used as heparin-mimics. 
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Experimental Section 
Typical polymerization procedure (HEAm Homopolymer Synthesis (DP 80)).  
BDMAT (16 mg, 0.06 mmol), HEAm (0.60 g, 5.1 mmol), phosphate buffer solution (2.7 mL), 
sodium hydroxide (3.3x10-2 mmol, 1.3 mg) and VA-086 (8.4x10-3 mmol, 2.4 mg) (from stock 
solution at 20.0 mg/mL) were introduced into a flask equipped with a magnetic stirrer bar and 
sealed with a rubber septum. The solution was deoxygenated by bubbling with nitrogen for 10 
minutes, and the vial was then placed in a temperature controlled oil bath at the desired temperature 
(90 °C), for the duration of time required to reach nearly full conversion (~ 2 hours). At the end of 
the reaction, the mixture was allowed to cool down to room temperature and then opened to the 
atmosphere. Final materials were characterised using 1H NMR spectroscopy and SEC (Mn,SEC and 
Ð were determined). The compound was then dialysed against water for 48 hours and freeze dried, 
to yield the final compound as a pale yellow powder; m.p > 300 °C; νmax/cm-1 3272 (m, COO-H 
and O-H, stretch), 2931 (w, C-H, stretch), 1633 (s, C=O, stretch), 1548 (s, N-H, bend), 1057 (s, 
C=S, stretch). 
 
Cell lines and cell culture 
NIH-3T3 cells were cultivated in Dulbecco’s modified eagle medium (DMEM) supplemented 
with 10 % bovine calf serum (BCS) and 1 % L-glutamine, at 37 °C and 5 % CO2 atmosphere. Cells 
were passaged every 3 days when reaching approximately 80 % confluency. NIH-3T3 cells were 
used up passage 16. BaF3-FR1c cells were cultivated in RPMI1640 GlutaMAX media 
supplemented with 10 % foetal bovine serum (FBS), 2 ng/mL of recombinant mouse IL-3, 600 
µg/mL of G418, at 37 °C and 5 % CO2 atmosphere. Cell media was replaced every 2-3 days by 
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centrifuging at 1000 rpm for 5 minutes and kept at a density between 500,000 to 1,000,000 
cells/mL and were used up to a month.  
 
Cytotoxicity assays on NIH-3T3 cells 
NIH-3T3 cells were washed with 10 mL of PBS, trypsinized and re-suspended in media. The 
cells were plated at a concentration of 2,000 cells/well in a 96-well plate and allowed to attach for 
12 hours. The medium was replaced with 100 µL of fresh medium containing a series of polymer 
dilutions ranging from 10 ng/mL to 1 mg/mL (10 ng/mL, 1, 10 and 100 µg/mL and 1 mg/mL). 
After an incubation of 48 hours at 37 °C and 5 % CO2, the cells were washed and the medium 
replaced with fresh culture medium containing 25 µL of XTT (1 mg/mL) and PMS (25 µmol/L). 
Cells were further incubated for 12 hours at 37 °C, 5 % CO2. Absorbance of each well was 
measured using a Synergy HTX plate reader at 475 nm and 650 nm (background) with A = A475nm 
- A475nm(blank) – A650nm. The viability of cells was normalised to samples in which cells were 
incubated with medium only (positive control = 100 %). Each sample had three replicates and the 
experiment was repeated two times.  
 
Haemolysis Study 
Defibrinated sheep red blood cells were prepared by washing the blood (2 mL) three times with 
PBS (750 µL) by ultracentrifugation (4,500 g for 1 minute) and removing the plasma each time. 
The blood was then diluted with PBS at 1:150. Polymers were dissolved in PBS and three serial 
dilutions were prepared, 10, 100 and 200 µg/mL. 380 µL of blood was mixed with 20 µL of 
polymer samples and incubated at 37 °C for 2 hours. The samples were then centrifuged at 1,000 
g for 10 minutes and then 200 µL of the supernatant was transferred into a 96-well plate and the 
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absorbance was read at 414 nm and normalised against a positive and negative control. A solution 
of 2 % of triton X-100 in PBS was used as a positive control and set at 100 % of haemolysis of red 
blood cells. 
 
Cell proliferation 
BaF3-FR1C cells were collected (1,000 rpm for 5 minutes) and washed twice (1,000 rpm for 5 
minutes) with medium to remove traces of IL-3 and G418. Cells were plated at a concentration of 
20,000 cells/well/50 µL in the internal wells of a 96-well plate in the presence of medium without 
IL-3 and G418. Further 50 µL of medium containing polymers or heparin and FGF at double the 
final desired concentration ([polymers]final = 100, 1 and 0.1 µg/mL and [FGF]final = 5 ng/mL) were 
added to the wells. Controls with cells only and with cells in the presence of 5 ng/mL of FGF were 
used as references. External wells were filled with 100 µL of PBS and a gas permeable moisture 
barrier seal (4titude) was used to decrease the evaporation into the plate. After incubation for 48 
hours at 37 °C, 5 % CO2, 20 µL of the CellTiter-Blue
® assay were added into each wells and 
further incubated for 6 hours at 37 °C, 5 % CO2. Fluorescence of each well was measured using a 
Synergy HTX plate reader with the excitation set to 560 nm and the emission at 590 nm. The 
extension of cell proliferation was calculated by using the wells containing cells in medium only 
as positive controls (100 %). Each sample had four replicates and the experiment was repeated 
four times. 
 
Cell proliferation applying thermal stressors 
Solutions of FGF alone, FGF with polymers or FGF with heparin were prepared in medium at 
double the final desired concentration ([polymers]final = 100, and 50 µg/mL and [FGF]final = 5 
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ng/mL). Solutions were then stored for 12 hours at the desired temperature either at approximately 
20 °C (room temperature) or 37 °C. BaF3-FR1C cells were collected (1,000 rpm for 5 minutes) 
and washed twice (1,000 rpm for 5 minutes) with medium to remove traces of IL-3 and G418. 
Cells were plated at a concentration of 20,000 cells/well/50 µL in the internal wells of a 96-well 
plate in the presence of medium without IL-3 and G418. A further 50 µL of polymers or heparin 
solution at double the final desired concentration were added to the wells. Controls with cells only 
and with cells in presence of 5 ng/mL of FGF with applied thermal stressors were used as 
references. External wells were filled with 100 µL of PBS and a gas permeable moisture barrier 
seal (4titude) was used to decrease the evaporation into the plate. After incubation for 48 hours at 
37 °C, 5 % CO2, 20 µL of the CellTiter-Blue assay was added into each wells and further incubated 
for 6 hours at 37 °C, 5 % CO2. Fluorescence of each well was measured using a Synergy HTX 
plate reader at set up at 560Ex/590Em. The extension of cells proliferation was calculated by using 
the well with cells with medium only as positive control (100 %). Each sample had four replicates 
and the experiment was repeated four times. 
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Results and Discussion 
Synthesis Polymeric Structures 
To compare the influence of the sulfonated polymer structure on the stabilisation of bFGF, a 
library of PAMPS homopolymers and copolymers with varying size, architectures and monomer 
distribution was synthesised by RAFT polymerisation in aqueous solution using previously 
reported conditions.34 bFGF was used in this study as it has been widely used in the literature to 
test the ability of polymers to mimic polymer.16, 28, 30 A library of AMPS® homopolymers with 
DPs ranging from 10 (Mn = 2,500 g/mol) to 400 (Mn = 91,000 g/mol) (Table S 1) were synthesised. 
Furthermore, as literature suggests that interactions between heparin and growth factors are further 
enhanced through hydrogen bonding between asparagine and glutamine residues and the hydroxyl 
group from heparin,8 a small library of PAMPS-co-PHEAm (random, diblock and octablock 
copolymers) was also prepared. These systems enable us to investigate the effect of monomer 
distribution for different ratios of AMPS® to HEAm whilst always targeting an overall DP of 80 
(Table S 2 and Figure S 2, Table S 3 and Figure S 3).35-36 Finally, a homopolymer bearing 
hydroxyl group only (PHEAm) was also prepared (Figure S 1) as non-sulfonated control. 
Reactivity ratios of AMPS® and HEAm were also determined, as monomer reactivity during 
polymerisation influence the monomer distribution in the final copolymer. Consequently, the 
apparent reactivity ratio of AMPS® and HEAm was determined using HPLC,37 by monitoring the 
consumption of AMPS® and HEAm during the synthesis of the random copolymer PAMPS40-co-
PEAHm40 (Figure S 5). The parallel decrease of each monomer peak intensity (SlopeAMPS
®
 = 
4.2x104 and SlopeHEAm = 3.1x10
4) suggests that the copolymer is composed of statistically 
distributed AMPS® and HEAm monomers. Finally, star polymers were synthesised, using an “arm 
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first” approach, where a copolymer is synthesised first (the ‘arms’), followed by addition of a 
difunctional vinyl monomer to form the ‘core’, as described in the literature, to investigate the 
influence of branching on heparin-mimicking properties.34 All polymers were dialysed against 
water for 48 hours, changing the water three times. Float-A-Lyzer® with a molecular weight cut 
off range between 0.5-1 kDa from Spectrum were used to remove any undesirable reactants (i.e. 
potential monomers leftover or initiator). 
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Table 1. Molecular weights and haemolytic activity of heparin and heparin mimicking polymers 
used in this study. 
Polymer Structure Mn,SEC (Ɖ) a 
(g/mol) 
10 
µg/mL b 
100 
µg/mL b 
200 
µg/mL b 
Heparin Heparin 16,400 -0.5 ± 0.1 0.0 ± 0.4 0.1 ± 0.1 
1 PAMPS10 - 0.1 ± 0.6 0.7 ± 0.7 1.7 ± 0.8 
2 PAMPS20 4,100 (1.10) 0.9 ± 0.7 -0.3 ± 0.3 0.3 ± 0.3 
3 PAMPS80 14,400 (1.19) 0.3 ± 0.6 0.0 ± 0.6 0.7 ± 1.1 
4 PAMPS200 30,500 (1.25) -0.2 ± 0.5 -0.3 ± 0.3 -0.3 ± 0.3 
5 PAMPS400 64,800 (1.51) 0.0 ± 0.3 -0.2 ± 0.9 0.0 ± 0.8 
6 PHEAm80 - 1.1 ± 0.4 -0.3 ± 0.6 1.8 ± 0.5 
7 (PAMPS10-b-PHEAm10)4 24,700 (1.25) 1.1 ± 0.2 0.6 ± 0.4 0.4 ± 1.0 
8 PAMPS24-b-PHEAm56 13,100 (1.18) 0.6 ± 0.5 0.5 ± 0.4 1.2 ± 0.3 
9 PAMPS40-b-PHEAm40 13,300 (1.21) 0.5 ± 0.2 0.8 ± 0.1 1.3 ± 0.4 
10 PAMPS56-b-PHEAm24 14,400 (1.23) 0.5 ± 0.5 0.8 ± 0.7 1.4 ± 0.3 
11 PAMPS24-co-PHEAm56 9,500 (1.15) 1.1 ± 0.7 1.6 ± 0.1 2.1 ± 0.2 
12 PAMPS40-co-PHEAm40 12,000 (1.15) 0.8 ± 0.5 0.8 ± 0.2 1.1 ± 0.9 
13 PAMPS56-co-PHEAm24 14,000 (1.16) 0.5 ± 0.4 0.8 ± 0.2 1.9 ± 0.7 
14 PAMPS50-Star 316,200 (1.01) -0.1 ± 0.4 0.5 ± 0.5 0.6 ± 0.6 
15 PAMPS100-Star 526,000 (1.01) -0.1 ± 0.2 0.0 ± 0.3 -0.2 ± 0.7 
16 (PAMPS10-b-PHEAm10)4-Star 1,482,000 (1.22) 1.4 ± 0.6 1.7 ± 0.5 2.0 ± 0.6 
17 PAMPS40-b-PHEAm40-Star 714,000 (1.01) 1.4 ± 0.2 2.1 ± 0.3 1.7 ± 0.9 
18 PAMPS40-co-PHEAm40-Star 436,000 (1.01) 1.6 ± 0.3 1.6 ± 1.2 0.2 ± 0.1 
a Experimental Mn,SEC values were determined by size-exclusion chromatography in 20 % MeOH / 80 % 0.1M NaNO3 in Milli-Q water eluent using 
the triple detection options in Agilent GPC/SEC Software which uses a combination of a Refractive Index (RI), a Multi-Angle Light Scattering 
(MALS) and a Viscometer (VS) detectors.; b Haemolysis of heparin mimicking polymers against defibrinated sheep blood red cells at 37 °C for 2 
hours, Triton X was used as positive control (100 %). 
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Toxicity of Polymers 
None of the materials displayed cytotoxicity at concentrations up to 1 mg/mL after 48 hours 
incubation with murine embryonic fibroblasts (NIH-3T3; in the absence of bFGF), as determined 
using an XTT assay.38 Of importance for wound healing formulations, the haemolytic activity of 
the synthesised polymers was then evaluated using PBS and Triton-X solutions as negative (0 %) 
and positive (100 %) controls, respectively. Following incubation with red blood cells for 2 hours 
at 37 °C at three different concentrations (10, 100 and 200 µg/mL), none of the polymers displayed 
any significant haemolytic activity (< 2.5 %) (Table 1). These results, being comparable to 
previously reported data, confirm that the polymers are non-toxic and non-haemolytic.39-40 
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Figure 1: Cell viability of NIH-3T3 fibroblasts incubated for 48 hours in the presence of varying 
concentrations (10 ng/mL, 1, 10 and 100 µg/mL and 1 mg/mL) of A) PAMPS with various DPs; 
B) PAMPS and PHEAm copolymers with varying percentages of charges, and C) star (co-) 
polymers. Cell viability was determined using typical protocol for XTT assay. Each data point 
represents the means of triplicates from two independent experiments (N = 6). The error bars 
represent the standard deviation of the mean.  
  
A) B)
C)
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Proliferation Study 
The propensity of PAMPS synthetic polymers to stabilise bFGF and promote cellular 
proliferation in the presence of bFGF was investigated. In these experiments BaF3-FR1c cells that 
have been modified to express the FGFR1c receptor but lack heparan sulfate proteoglycans on 
their surface were used. Absence of heparan sulfate proteoglycans is important as these may 
interfere with the activity of our heparin mimicking polymers.12 An overall increase in cell 
proliferation indicates an increase of bFGF stabilisation and dimerisation. Control experiments 
revealed no increase of cellular proliferation when BaF3-FR1c cells were incubated with bFGF 
alone, whilst the presence of heparin resulted in a concentration dependent increase in cellular 
proliferation of about 300 to 500 %, (Figure 2 – A and Table S 5, , 115 ± 17 %, p < 0.001),  in 
agreement with literature.28 
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Figure 2: Proliferation of BaF3-FR1c cells incubated for 48 hours at 37 °C in the presence of 5 
ng/mL of bFGF A) PAMPS homopolymers with various DPs at various concentrations (0.1, 1 and 
100 µg/mL); B) PAMPS homopolymers with various DPs at 100 µg/mL; C) PAMPS and PHEAm 
copolymers with varying percentages of charges and monomers segmentations at 100 µg/mL; D) 
star-shaped (co-)polymers at 100 µg/mL. Cell growth was determined using typical protocol for 
CellTiter-Blue® assay. Data were normalised (100 %) to values obtained for cells incubated with 
culture medium only. Each data point represents four replicates of four independent experiments 
(N = 16). The error bars represent the standard deviation from the mean. Statistical analyses were 
performed with an ANOVA, then Tukey HSD post-hoc test using SPSS software, results can be 
found in the supporting information. 
A) B)
C) D)
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Effect of Molecular Weight 
 
The effect of molecular weight on bFGF stabilisation was studied using AMPS® homopolymers 
with increasing degrees of polymerisation from 10 to 400. The variation of proliferation for various 
AMPS homopolymers appeared to be both concentration and molecular weight dependant. 
Considerably higher proliferation was observed when incubating bFGF with 100 µg/mL of 
polymers rather than with 0.1 or 1 µg/mL (Table S 5), which is similar to what is observed in the 
case of heparin. The maximum proliferation value of synthetic polymers was reached for PAMPS80 
(392 ± 24 %). The proliferation obtained with PAMPS80 was comparable to that obtained for 
heparin at 100 µg/mL (481 ± 27 %, p < 0.001 (heparin)) (Table S 6). To understand this 
phenomenon, the experimental average molecular weight of the various synthetic AMPS® 
homopolymers was compared to that of heparin (Figure 3 – A and B). The results confirm that 
PAMPS80 experimental molecular weight is closest to that of heparin (~ 15,000 g/mol), suggesting 
that there is an optimal size range for bFGF activation.1, 16 The importance of size could be linked 
to differences in the propensity of polymers with different lengths to induce dimerisation of the 
growth factor, a phenomenon which has been observed in the past for heparin.12 Chains smaller 
than the optimal length are less likely to bind to two bFGF units and provoke their dimerization. 
Additionally, they are less likely to bind to both the dimeric form of bFGF and FGFR1c. In 
contrast, while longer polymeric chains can bind to multiple copies of bFGF, their flexible nature 
does not constrain the proteins into near proximity, which in turn does not promote the dimerisation 
of bFGF and its binding to FGFR1c. Interestingly, these results are in contrast with those obtained 
by Maynard et al., who demonstrated that the molecular weight of P(SS-co-PEGMA) copolymers 
did not affect cellular proliferation.30 This difference could be due to the PEGMA monomer the 
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authored used, as its high molecular weight may induce significantly higher steric hindrance. 
However, PSS and PAMPS are different polymers and cannot be compared directly but only a 
trend can be deduced. Polymers made by the same technic and with similar molecular weights (or 
DP) would be easier to compare with each other’s. 
 
  
Figure 3: A) Molecular weight of selected linear PAMPS and heparin, as determined using size-
exclusion chromatography with triple detection; B) Molecular weight distributions of heparin 
sample used in this study and PAMPS80, as determined using size-exclusion chromatography with 
triple detection. 
Effect of Comonomer and Monomer Distribution  
 
Incubation in the presence of a non-sulfonated polymer control, PHEAm homopolymer (DP = 
80), showed a relatively small increase in cellular proliferation (145 ± 27 % with 100 µg/mL of 
PHEAm80, p < 0.001 (heparin) and p = 0.71 (FGF)) as compared to heparin (Figure 2 – C and 
Table S 7). This result is in accordance with the accepted mechanism of interaction between 
heparin and bFGF, which mostly relies on electrostatic interactions between heparin’s sulfated 
A) B)
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groups and the positively charged arginine and lysine rich domain of bFGF.41 It is noteworthy that 
the theoretical molecular weight of PHEAm (9,500 g/mol) is lower than PAMPS80 (18,600 g/mol), 
meaning that at equivalent mass concentrations, twice as many molecules of PHEAm are present 
in the system. Next, the activity of copolymers of AMPS® and HEAm was investigated using a 
library of copolymers with varying segmentation (random, octablock and diblock) and percentage 
of charges (30 %, 50 %, and 70 %) (Figure S 4). At 100 µg/mL and in the case of copolymers 
with 50 % of AMPS®, differences in cell proliferation were observed with changing block 
segmentation, from random (12, 149 ± 21 %) to octablock (7, 250 ± 30 %) and finally diblock (9, 
362 ± 18 %) copolymers (Figure 2 – C and Table S 7, p < 0.001). While the overall proliferation 
remains still lower than heparin or PAMPS80, the highest results are obtained with the diblock 
copolymer, yet with only half the number of sulfate groups. This can be attributed to the 
compartmentalisation of anionic charge in a particular section of the polymer chain (i.e for the 
diblock compared to the octablock or random copolymers). This could increase the affinity for the 
cation-rich heparin-binding section of bFGF and FGFR1c. A similar hypothesis was suggested by 
Garcia-Fernandez et al.32 who attributed the enhanced heparin-mimicking activity of partially 
segmented poly(BA-co-AMPS), synthesised by free radical polymerisation, to a higher propensity 
of the AMPS-rich blocks to form the helical conformation required to interact with the heparin 
binding site of bFGF.42 Interestingly, increasing the percentage of AMPS compared to HEAm 
from 30 to 70 % had a negligible influence on the proliferation activity induced by both the random 
and diblock copolymeric system (Figure 2 – C and Table S 7, p < 0.001). On one hand, this further 
indicates that hydrogen bonding does not play an important role in the interaction process.43-44 On 
the other hand, the degree of charge present on the chain may not matter as much as charge 
segregation.  
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Effect of Polymer Architecture 
 
To further study the importance of size on bFGF stabilisation, a range of larger branched star-
shaped copolymers were investigated. The experiments, shown in Figure 2 – D, showed lower 
proliferative activity (300 ± 26 % for PAMPS50-Star (14) and 311 ± 43 % for PAMPS100-Star (15)) 
compared to the linear polymers (392 ± 24 % for PAMPS80 (3)). Unlike their linear counterparts, 
none of the star copolymers (random versus diblock versus octablock star copolymers) showed 
higher cellular proliferation compared to when heparin is used (Table S 8, p = 1.000). Direct 
comparison between star and linear polymers is difficult due to the dramatic difference in 
molecular weight. However, the lower proliferation observed is likely due to the lower mobility of 
the arms in the star structure, in comparison with their unbound linear homopolymer counterparts. 
The steric hindrance of the polymeric arms in the star architecture potentially results in bFGF being 
only able to bind onto the surface of the polymer structure, thus decreasing opportunities for bFGF 
dimerisation. In addition, for the star copolymers the surface is covered by a mixture of AMPS 
and HEAm, this is expected to further reduce opportunity for bFGF dimerization 
 
Effect of Temperature 
 
bFGF is known to degrade during storage and delivery, thus reducing its efficacy and 
applicability caused by denaturation at around 40 °C.29, 45 The electrostatic stabilisation between 
the protein and heparin has been shown to significantly increase the denaturation temperature, 
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improving performance.46-47 The stabilisation of bFGF with the highest performing polymers (i.e. 
PAMPS80, PAMPS40-b-PHEAm40, PAMPS50-Star and heparin itself) was studied at different 
temperatures (20 °C or 37 °C for 12 hours) applied to mimic potential storage conditions, and 
compared to bFGF alone (Figure 4). After storage at room temperature and at 37 °C for 12 hours, 
all of the linear polymers (heparin, PAMPS80, PAMPS40-b-PHEAm40) showed a 20-40 % decrease 
in relative cellular proliferation compared to when no stressors were applied. These were similar 
to what was observed for bFGF alone (Table S 9, p ≤ 0.05). 
 
 
Figure 4: Relative cell proliferation of BaF3-FR1c compared to when no stressors were applied 
on bFGF with or without polymer or heparin. bFGF (5 ng/mL) was pre-incubated at the indicated 
temperatures for 12 hours with or without polymers or heparin at 100 µg/mL. Cell growth was 
determined using typical protocol for CellTiter-Blue® assay. Data were normalised to cellular 
proliferation without stressors. Each data point represents four replicates of two independent 
experiments (N = 8). The error bar represents the standard deviation from the mean. Statistical 
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analyses were performed with an ANOVA, then Tukey HSD post-hoc test using SPSS software, 
results can be found in the supporting information. 
 
After storage of bFGF at 37 °C during 12 hours with heparin, a decrease in bioactivity was 
observed from 1 ± 0.18 to 0.78 ± 0.02 and 0.71 ± 0.15 at 100 µg/mL. This is in accordance with a 
previous observation that heparin acts as a natural stabiliser for bFGF.3 Overall, the relative cell 
proliferation was shown to decrease when the storage temperature was increased respectively to 
room temperature and finally 37 °C. Finally, no improvement of bFGF stability was observed in 
the presence of the star polymers during storage at any temperatures. This can be attributed to a 
weakened affinity between the star polymers compared to when linear polymers are used with 
bFGF at increased temperature due to the potential breakdown of electrostatic interactions.48-49 
Additionally, it was previously hypothesised that the binding of the star polymers happen only 
onto their surface which is likely due to the difference of conformation between linear and star 
polymers. This probably weakened the interaction between bFGF and star polymers compared to 
linear polymers. 
 
Conclusions 
 
Here, the efficiency of PAMPS-based synthetic heparin-mimicking polymers for the 
stabilisation of bFGF, determined using the proliferation of BaF3-FR1c cells as a model assay, has 
been demonstrated. The results indicate that the stabilising properties of AMPS® homopolymers 
are length-dependant, with the optimal length matching that of naturally occurring heparin. 
Investigating a range of copolymers of AMPS® and HEAm showed that charge distribution has a 
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significant influence, with the highest charge density showing the highest proliferation activity 
(i.e. diblock > octablock > random copolymer). Branched architectures in the form of star polymers 
showed an overall decrease in bFGF stabilisation activity, which we attribute to the binding of 
bFGF onto the surface of the star polymers only, affecting both the binding of two copies of bFGF 
and consequently the dimerisation. However no significant improvement in stabilisation was 
evident after applying thermal stressors to bFGF in the presence of any of the synthesised 
polymers. 
Supporting information 
SI contain Materials, Instrumentations, Equations, Synthesis Details, NMR results, GPC 
spectrum and statistical test. 
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